Cited by

• Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment.

  Pisani F, Fazio A, Spina E, Artesi C, Pisani B, Russo M, Trio R, Perucca E. Pisani F, et al. Psychopharmacology (Berl). 1986;90(3):295-8. doi: 10.1007/BF00179180. Psychopharmacology (Berl). 1986. PMID: 3097715
• Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant?

  Pinder RM. Pinder RM. Neuropsychiatr Dis Treat. 2005 Mar;1(1):3-7. doi: 10.2147/nedt.1.1.3.52293. Neuropsychiatr Dis Treat. 2005. PMID: 18568121 Free PMC article.
• A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.

  Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, Chowdhry F, Cutler AJ, Jones NJ, Findling RL, Schwabe S. Nasser A, et al. J Clin Psychopharmacol. 2021 Jul-Aug 01;41(4):370-380. doi: 10.1097/JCP.0000000000001404. J Clin Psychopharmacol. 2021. PMID: 34181360 Free PMC article. Clinical Trial.
• New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties.

  Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. Yu C, et al. J Exp Pharmacol. 2020 Aug 25;12:285-300. doi: 10.2147/JEP.S256586. eCollection 2020. J Exp Pharmacol. 2020. PMID: 32943948 Free PMC article.
• Age-related differences in kinetics and side-effects of viloxazine in man and their clinical implications.

  Altamura AC, Melorio T, Invernizzi G, Colacurcio F, Gomeni R. Altamura AC, et al. Psychopharmacology (Berl). 1983;81(4):281-5. doi: 10.1007/BF00427563. Psychopharmacology (Berl). 1983. PMID: 6419255